Comparative Pharmacology
Head-to-head clinical analysis: AMINESS 5 2 ESSENTIAL AMINO ACIDS W HISTADINE versus EPANOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINESS 5 2 ESSENTIAL AMINO ACIDS W HISTADINE versus EPANOVA.
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE vs EPANOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Intravenous infusion: 500 mL of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
4 g orally once daily as 4 capsules of 1 g each with food.
None Documented
None Documented
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution